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1. Introduction
1.1. Roles of glycans on diverse aspects of biological activities
Regardless of species, all the living organisms have poly-saccharides called glycans in their
cellular surfaces or even inside the cells. The biological roles of carbohydrates are particularly
important in the assembly of complex multicellular organs, which requires interactions
between cells and the surrounding matrix. All cells and numerous macromolecules in nature
carry an array of covalently attached sugars (monosaccharides) or sugar chains (oligosacchar‐
ides). Because many glycans are on the outer surface of cells or secreted macromolecules, they
are acting to modulate or mediate a wide variety of events in cell to cell, cell with matrix, and
cell with proteins or lipids critical to the development and function of complex forms of
multicellular organisms (Rademacheret al., 1988; Sharon and Lis, 1993; Varki, 1993).
Glycans also function as mediators in the interactions between different organisms, for
example, between hosts and infectious agents or symbionts. In addition, simple, rapidly
turning over, protein-bound glycans are abundant within the nucleus and cytoplasm, where
they act as regulatory switches. Therefore, as a complete paradigm of biology, glycans should
be included quite often in covalent combination with other macromolecules such as glyco‐
proteins and glycolipids, so called glycoconjugates (Gagneux and Varki, 1999).
Figure 1 provides a listing of known glycan-protein or glycan-lipid linkages in nature. The
common classes of glycans found in or on eukaryotic cells are primarily defined according to
the nature of the linkage to the targets. A glycoprotein is a glycoconjugate in which a protein
carries one or more glycans covalently attached to a polypeptide backbone, usually via N or
O linkages. An N-glycan (N or asparagine-linked oligosaccharide) is a sugar chain covalently
attached to an asparagine residue of a polypeptide chain at the consensus peptide sequence:
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Asn-X-Ser/Thr. A mucin is a large glycoprotein that carries many O-glycans that are clustered.
A proteoglycan is a glycoconjugate that has one or more glycosaminoglycan (GAG) chains
attached to a “core protein” through a typical core region ending in a xylose residue that is
linked to the hydroxyl group of a serine residue. The distinction between a proteoglycan and
a glycoprotein is otherwise arbitrary, because some proteoglycan polypeptides carry both
glycosaminoglycan chains and different O- and N-glycans. A glycophosphatidylinositol
anchor is a glycan bridge between phosphatidylinositol and a phosphoethanolamine that is in
amide linkage to the carboxyl terminus of a protein. This structure typically constitutes the
only anchor to the lipid bilayer membrane for such proteins. A glycosphingolipid (often called
a glycolipid) consists of a glycan usually attached via glucose or galactose to the terminal
primary hydroxyl group of the lipid moiety ceramide, which is composed of a long chain base
(sphingosine) and a fatty acid. Glycolipids can be neutral or anionic. A ganglioside is an anionic
glycolipid containing one or more residues of sialic acid. It should be noted that these represent
only the most common classes of glycans reported in eukaryotic cells. There are several other
less common types found on one or the other side of the cell membrane in animal cells (Varki,
1997; Fuster and Esko, 2005).
From Essentials of Glycobiology second edition (2007)
Figure 1. Glycans on surface or inside the cells
T-Cell Leukemia - Characteristics, Treatment and Prevention90
As can be imagined from their ubiquitous and complex nature, the biological roles of glycans
are quite diverse spanning the spectrum from those that are subtle to those that are crucial for
the development, growth, function, or survival of an organism. The diverse functions attrib‐
uted to glycans can be divided into two general categories: (i) structural and modulatory
functions (involving the glycans themselves or their modulation of the molecules to which
they are attached) and (ii) specific recognition of glycans by glycan-binding proteins, called
lectin. Expression of certain sets of glycans in intact organisms are found exquisitely specific
temporal and spatial patterns those glycans in relation to cellular activation, embryonic
development, organogenesis, and differentiation. Certain relatively specific changes in
expression of glycans are also often found in the course of transformation and progression to
malignancy, as well as other pathological situations such as inflammation. These spatially and
temporally controlled patterns of glycan expression imply the involvement of glycans in many
normal and pathological processes, the precise mechanisms of which are not well understood
(Theocharis, 2010; Hynes and Naba, 2012).
2. Glycans as the markers of cancer
Tumor cells undergo alteration of intracellular signalings to promote cell cycle progression
and rapid growth, adhere to a variety of other cell types and cell matrices, and invade tissues.
Embryonic development and cellular activation in vertebrates are typically accompanied by
changes in cellular glycosylation profiles. It is therefore rational that glycosylation changes are
also a typical feature of malignant transformation and tumor progression. The earliest evidence
came from observing that plant lectins showed enhanced binding to and agglutination of
tumor cells. Next, it was found that in vitro transformation was frequently accompanied by a
general increase in the size of metabolically labeled glycopeptides produced by trypsinization
of surface molecules from cancer cells (Hakomori and Kannagi, 1983). With the advent of
monoclonal antibody technology in the late 1970s, investigators found many “tumor-specific”
antibodies which were directed against glycan epitopes, especially those borne on glycosphin‐
golipids (Feizi, 1985). In most cases, further studies showed that these epitopes were also
expressed in embryonic tissues and, in a few cell types, in the normal adult (Fukuda, 1996).
Significant correlations between certain types of altered glycosylation and the prognosis of
tumor-bearing animals or patients increased interest in these changes. In several instances, in
vitro cellular assays and in vivo animal studies have further supported the view that these
changes are critical to aspects of tumor cell behavior (Kannagi et al., 2004).
3. HTLV-1 causes complicated forms of diseases to human
Human T-lymphotropic virus type 1 (HTLV-1) is the first and unique oncogenic retrovirus
that infects 20 million more people worldwide (Hinuma et al., 1992; Proietti et al., 2005;
Gonçalves et al., 2010; Sonoda et al., 2011). Among these infected individuals, 2 to 5% develop
aggressive and mostly fetal adult T cell leukemia/lymphoma: ATL (Yoshida, 2010; Iwanaga et
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al., 2010), and a further 1 to 2% develop a variety of chronic inflammatory syndromes, known
as HTLV-1–associated myelopathy/tropical spastic paraparesis: HAM/TSP (Osame et al.,
1986) and HTLV-1–associated uveitis: HU (Mochizuki et al., 1992). HTLV-1 has also linked,
even with less definitive epidemiologic proof, dermatitis (La Grenade et al., 1990; Amano et
al., 2011), polymyositis (Inose et al., 1992), synovitis (Nishioka et al., 1989; Sowa, 1992),
thyroiditis (Kawai et al., 1991) and bronchio-alveolar pneumonitis (Kimura et al., 1989). While
the pathophysiologies of patients with HAM/TSP and HU have relatively been well controlled,
the efficacy of present treatment procedures to ATL are quite insufficient and leading ATL as
one of the worst blood cell malignancies to cure (Olière et al., 2011; Tsukasaki, 2012). Re‐
searchers hence are trying to develop any diagnostic tools enabling to identify the high risk
carriers (who may develop ATL) in the early phase of infection.
HTLV-1 seropositivity is corresponding to the modes of transmission: from mother to child,
predominantly through breast feeding as the initiation for common course of ATL develop‐
ment (Hino et al., 1985); via sexual intercourse and via parenteral transmission by transfusion
of infected cellular blood products or sharing of needles and syringes as the courses for HAM/
TSP or HU onset (Manns et al., 1991, Proyetti 2005). HTLV-1 infection mostly happens to CD4
T-lymphocytes (Gallo et al., 1982), and multiple viral proteins are produced from the provirus.
Among those viral proteins, HTLV-1 trans-activator protein Tax, which promotes the early
events of oncogenic process including its own long-terminal-repeat (LTR) transcription
(Fujisawa et al., 1985), activates several major cellular transcription factor pathways, such as
nuclear factor (NF)-kappaB (Ruben et al., 1988; Yamaoka et al., 1998), cAMP response element
binding protein (CREB)/AP-1 transcription factor (ATF, Andrisani et al., 1990; Xu et al., 1990;
Himes, 1993), and serum response factor (SRF, Fujii et al., 1991), all of which eventually mediate
viral immortalization. Tax targeted genes include interleukin (IL)-2 and the IL-2alpha receptor
(Tac or CD25), which initiate and sustain an autocrine pathway of T-cell activation (Ruben et
al., 1988). On the late stage of ATL development, infected cell undergoes extensive genetic
alterations and some of these populations induce aberrant micro-RNA expression (Yeung et
al., 2008) resulting in overexpression of NIK, a strongest NF-kappaB inducing MAP3 kinase,
and cells eventually become independent from Tax-mediated NF-kappaB signaling (Yama‐
gishi et al., 2012). Finally, another HTLV-1 encoded oncogenic trans-activator, HTLV-1-basic-
zipper protein (HBZ), induces Foxp3, a transcription factor necessary for maintenance of the
regulatory T-cell phenotype, to develop immune-suppressive environment which is favorable
to establish malignant phenotype of ATL (Gaudray et al., 2002; Satou et al., 2008).
ATL cells display several characteristic ‘ATL-specific’ cell surface markers such as CD25, OX40,
and TSLC1 (Teshigawara et al., 1985; Baum et al., 1994; Sasaki et al., 2005). Japanese HTLV-1
cohort study group, however, have reported that the most reliable molecular based definitive
risk factors for the development of ATL among asymptomatic HTLV-1 carriers are baseline
proviral load higher than 4 copies/100 peripheral blood mononuclear cells. Although advanced
age, family history of ATL, and first opportunity for HTLV-1 testing during treatment for other
diseases have also determined as the independent risk factors for ATL prognosis (Iwanaga et
al., 2010), we still do not know how many cellular factors and to what extent in HTLV-1 infected
subjects contribute to ATL pathogenesis nor which biomarkers distinctly determine the wide
T-Cell Leukemia - Characteristics, Treatment and Prevention92
ranges of ATL pathological conditions (i.e., smoldering, chronic or acute leukemia or lym‐
phoma).
4. Linkage between efficacy and subtypes of ATL symptoms
Shimoyama (1991) first proposed the diagnostic criteria to classify four clinical subtypes of
ATL: (1) Smoldering type, 5% or more abnormal lymphocytes of T-cell nature in PBL, no
hypercalcaemia (corrected calcium level less than 2.74 mmol/l), lactate dehydrogenase (LDH)
value of up to 1.5 x the normal upper limit, no lymphadenopathy, no involvement of liver,
spleen, central nervous system (CNS), bone and gastrointestinal tract, and neither ascites nor
pleural effusion. Skin and pulmonary lesion(s) may be present. (2) Chronic type, absolute
lymphocytosis (4 x 109/l or more) with T-lymphocytosis more than 3.5 x 109/l, LDH value up
to twice the normal upper limit, no hypercalcaemia, no involvement of CNS, bone and
gastrointestinal tract, and neither ascites nor pleural effusion. Lymphadenopathy and in‐
volvement of liver, spleen, skin, and lung may be present, and 5% or more abnormal T-
lymphocytes are seen in PBL in most cases. (3) Lymphoma type, no lymphocytosis, 1% or less
abnormal T-lymphocytes, and histologically-proven lymphadenopathy with or without
extranodal lesions. (4) Acute type, remaining ATL patients who have usually leukemic
manifestation and tumor lesions, but are not classified as any of the three other types. Smol‐
dering and chronic subtypes are indolent but once these group become acute subtype, the
mean survival period even with the best protocol of chemotherapy, mLSG15, is only 13 months
and overall two year survival ratio is only 25% (Tsukasaki, 2012).
To improve the poor prognosis of ATL, new chemical combinations or new biological
treatment, including antibody targeting, immune activation by vaccination or bone marrow
transplantation have developed (Tsukasaki et al., 2009; Nasr et al., 2011; Nakano and Wata‐
nabe, 2012).
Bazarbachi and his colleagues reported that treatment in combination of anti-virus drug
zidovudine (AZT) and interferon-alpha (IFN-α) have dramatically improved the five year
survival rate of ATL patients up to 46% (Bazarbachi et al., 2010). AZT/ IFN-α protocol is the
most promising for ATL treatment at present but it is not omnipotent for the following reason.
This study was applied for all four different ATL subtypes and achieved 77% five-year survival
rate for smoldering/chronic and 28% for acute subtype respectively. For lymphoma subtype
however this protocol had no effects with 7-month median and no further survival beyond 18
month after treatment. This result clearly indicated that the novel fine and reliable subtype-
specific diagnostics for asymptomatic but high-risk carriers are urgently required.
5. Glycans as the potential biomarkers for ATL subtypes
It’s been thirty seven years since Van Beek reported the relationship between the malignancy
and glycoprotein distribution on the surface of leukemic cells (Van Beek et al., 1975). Then
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Dnistrian claimed the plasma lipid-bound sialic acid as a diagnostic marker for hematologic
tumors as well as other carcinomas (Dnistrian and Schwartz, 1981). Ohmori and his colleagues
first reported that a distinct type of sialyl Lewis X antigen is selectively expressed on helper
memory T cells and also on ATL cells which are defined by the monoclonal antibody 2F3
(Ohmori et al., 1993) and Sanada et al. reported that ATL patient’s levels of serum hyaluronic
acid moved in parallel with the clinical activity of their disease (Sanada et al., 1999). These
reports clearly indicate that glycans should play very important roles on a tumorigenic
development of hematologic malignancy. However the complicated nature of carbohydrates
have hindered the development of diagnostic tools providing a statistically reliable values
which eventually define the linkage between glycans and tumor malignancies. To do so, this
device should quantitate the amount of multiple forms of glycans at one time and perform
multivariate analysis.
6. Lectin microarray as the profiler of ATL cell pathogenic development
There are basically three major processes in glycomics research: (1) glycan synthesis, (2) glycan
structural analysis and (3) glycan functional analysis. Glycan structural analysis is considered
the first priority as it elucidates the biological functions of the glycans. It is not that simple as
DNA or peptide sequencing is resolving most of questions because glycans are not linear-chain
molecules but having varieties of branching molecular structures.
Our strategy in glycomics takes a different approach from that used in genomics. We have
adopted the use of lectins as so-called “biological decipherers” of glycan structures, capitaliz‐
ing on their binding specificity to glycan structures. Further, a microarray strategy allows us
to utilize a number of lectins with different specificity thereby enabling ‘glycome’ analyses of
small sample amounts with high sensitivity and high throughput (Kuno A et al., 2005).
Mass spectroscopy (MS) is one possible alternative approach used in glycomic structural
analysis. MS potentially is a very powerful tool; however it is not versatile enough to be
used since MS is not suitable for differentiation of isomers, analysis of O-glycans, and not
applicable for crude samples. MS basically requires fairly large samples sizes (>100 μg of
proteins) due to its low resolution. Additionally, pre-treatment of the samples on glycan
structural analysis by MS is time consuming and bothersome (Pre-treatments requires the
isolation  of  glycoproteins,  cleaving  of  the  glycans  from  the  core  proteins,  and  those
labeling). From those practical views, the lectin microarray methodology is potentially very
powerful  for  glycomic  analysis:  (1)  quick  and  easy  to  use:  structural  profiling  can  be
performed directly on fluorescence-labeled glycoproteins; no need of glycan cleavage from
proteins,  (2)  highly sensitive:  1 -  100 ng order of  glycoproteins is  good enough, and (3)
high-throughput:  benefit  of  microarray format.  To note however,  the inference perform‐
ance of the lectin microarray may not be sufficient as that of MS.
One of the most noteworthy features of basic glycomics research is the weak interaction of
glycans and lectins (by more than two orders of magnitude) compared with that of antibodies
and antigens as well as nucleotide’s hydrogen bonds. This fact inevitably created a need for a
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new technology which is capable of detecting very weak glycan-lectin interactions directly
from a liquid phase without any washing process that is indispensable in DNA microarrays
or in ELISA assays to remove non-specific bindings and extra amounts of labeled molecules
floating in the liquid phase.
The GlycoStationTM and LecChipTM (lectin microarray containing 45 different lectins immobi‐
lized on a slide glass, GP Biosciences, Japan) employs novel ‘evanescent-field fluorescence
excitation (EFFEX)’ technologies were thus developed to obtain specific and highly sensitive
glycan-lectin interactions without washing (Fig. 2A). In this scanner, the excitation light bundle
incidents into a slide glass from the edge at an appropriate incident angle to form total internal
reflection at the interfaces between slide glass and sample solution. A configuration adopted
in this scanner will be the simplest and easiest one which is able to generate the evanescent-
filed as large as slide glass size (US Patent 6,787,364,2004). Under such conditions, an evanes‐
cent-field is formed on the surface of the lower refractive index side. The strength of
evanescent-field decreases exponentially as the distance increases from the slide surface. The
evanescent-field depth defined by the distance that the field strength drops to 1/e ranges from
100 nm to 200nm (it depends on the wavelength of excitation light adopted). Because of this
nature, floating glycans in a liquid phase only shows very low excitation in the evanescent
field, but glycans interacting with lectins can be excited effectively (Fig. 2B) and very weak
molecular interactions between glycans and lectins are monitored efficiently from the liquid
phase samples without any washing (Fig. 2C). GlycoStation can be used for screening and
understanding how partial glycan structures on cell surfaces change depending on the
condition of the cells (i.e., cancer, disease, cell differentiation stage and so on); and to elucidate
the roles glycans play and to understand the correlation between glycoforms and cell condi‐
tions. We therefore applied this system for evaluation of ATL cell pathogenic developments.
7. Lectin microarray reveals ATL cell specific lectin binding profiles
Conventional diagnosis on leukemia/lymphoma basically takes the following three methods,
(1) microscopic observation of tumor cell morphologies with staining by Giemsa, HE/MPO,
(2) quantitation of cellular surface marker molecules (glycoproteins usually) with fluorescence
activated cell sorter (FACS), and (3) karyotypic or molecular genetic diagnosis on chromosome
DNA. All these techniques require expertise and sometimes, especially through microscopic
observations, diagnosis varies because of their less quantitative nature.
In the case of ATL diagnosis, as mentioned above, four different subtypes are classified by PBL
counts and antibodies against HTLV-1 glycoproteins, biochemical values (calcium and LDH),
and morphological observations of HTLV-1 infected lymphocytes. Cellular surface markers
such as CD4, CD25 and provirus load are also measured for detailed analysis. Even with these
criteria, however, early diagnosis for these subtype classification is not applicable.
Therefore, we may explore to see how accurately lectin microarray identifies the subtypes
of ATL with multiple lectin-glycan interaction (LGI) values by Lectin array/ Glycostation.
As a preliminary experiment, we evaluated the LGI values of the following six different of
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cell,  (1)  two subjects  of  CD3+,  CD4+ Helper T-cells  (PBL-M, PBL-I)  from healthy volun‐
teers,  (2)  two subjects of HTLV-1 transformed cells (C8166,  ED),  and (3)  two subjects of
CD25+ ATL patient’s peripheral blood cells (ATL4, ATL9). While PBL showed uniformly
distributed relatively small cells, all ATL cells are large (twice as PBL-M or -I). ATL cells
show aggregation clusters  (glycans  might  be  involved in  these  morphogenesis)  and the
extents of aggregation in these four subjects are, from high to low, in order of C8166, ATL4,
ATL9 and ED (no aggregation, Fig. 3A). Then, we evaluated NF-κB activation level of these
six subjects by western blot (WB) analysis (Fig. 3B). To evaluate how NF-κB is activated,
cellular lysates from six subjects were fractionated into cytoplasmic (Cyt) and nuclear (Nuc)
fractions.  PBLs  from healthy  carriers,  of  course,  don’t  express  Tax  (lane  1  to  4),  C8166
expresses Tax in highest level (lane 8, 9), ATL4 and AT9 express less amount (lane 5 to 8)
and ED doesn’t (lane 11, 12). In accordance with Tax expression, the amount of I-κBα was
decreased in C8166 most and in ATL4 next. Two PBLs show the same levels of I-κBα and
in the case of ATL9 and ED, I-κBα was accumulated in cytoplasm with very high amount.
p65, a main species of NF-κB then accumulated in nucleus in C8166 most and, surprising‐









Figure 2. Principles and devices of LecChip lectin microarray
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Figure 3. Cell aggregation characteristics and Tax-NF-κB activation properties of ATL cells
From these observations, we concluded the characterizations of these cells as follows; (1) C8166
and ATL4 are to be characterized as Tax-high and heavy cell aggregation types, (2) ATL9 is
Tax-low and moderate cell aggregation type, and (3) ED is no-Tax and dispersed type. One
can imagine that the former type is sticky and accumulate easily to peripheral lymph nodes
and the latter is circulating in the blood vessels as leukemic cells.
Taking cytological characteristics mentioned above into consideration, we evaluated mem‐
brane glycoprotein fractions extracted from the six subjects by LecChipTM / GlycoStationTM.
Two PBLs showed very similar glycan profiles, but the other ATL samples showed various
glycan profiles. Concretely speaking, the expression levels of glycans interacting with nine
different lectins (AAL, MAL, PHA(E), DSA, ACG, LEL, Jacalin, ACA, WGA) were higher in
C8166 comparing with PBL, and inversely seven different lectins (SNA, SSA, TJA-I, NPA,
GNA, HHL Calsepa) showed lower interaction to those of C8166. In the case of ATL4, eight
out of nine lectins (except for WGA) listed in C8166 showed higher interactions, and the same
set of seven lectins showed lower profiles. One thing we have to emphasize here for ATL4 is
that SNA, SSA, TJA-I which have binding specificity to α 2,3-NeuAc showed significantly
lower expression comparing with others. In the case of ATL9, the six lectin interactions
(RCA120, PHA(E), DSA, BPL, PWM, Jacalin) were higher, and five lectins (NPA, GNA, HHL,
TxLC-I, EEL) were lower. Finally, in the case of ED, seven lectins (AAL, PHA(E), DSA, LEL,
Jacalin, WGA) interact higher, and other seven lectins (SNA, SSA, TJA-I, NPA, GNA, HHL,
EEL) got lower.
Using those digitized lectin intensities, we performed clustering analysis of these six subjects
by NIA Array Analysis (http://lgsun.grc.nia.nih.gov/ANOVA/). Fig. 4 shows the clustering
results. It is easily appreciated that (1) two PBLs behave very similar manners, (2) C8166 and
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ATL4 form the same cluster, (3) ED, non-Tax and dispersed, distinctive from other three cell
lines, showed larger distance from others, and (4) ATL9, low-Tax and moderate cell aggrega‐
tion, positioned between ED and C8166, ATL4.
Figure 4. Hierarchical clustering of the six subject’s glycan profiles
These results indicated that lectin microarray analysis detected the subtle differences of glycan
profiles which synchronized with Tax-expression, NF-κB activation and cellular aggregation
behaviors and this novel method would provide a diagnostic criteria for ATL’s pathological
development.
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